Lyell Immunopharma revenue LYEL

Sales by quarter and over the last twelve months, from 2020.

Lyell Immunopharma's revenue was $27K over the twelve months to Jun 30, 2026, down 55% on a year earlier.

In its latest quarter, Q2 FY26, it was $4K, down 50% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 66% a year on average.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	$4K	−50%	$27K
Q1 FY26	Mar 31, 2026	$2K	−71%	$31K
Q4 FY25	Dec 31, 2025	$6K	−45%	$36K
Q3 FY25	Sep 30, 2025	$15K	−56%	$41K
Q2 FY25	Jun 30, 2025	$8K	−38%	$60K
Q1 FY25	Mar 31, 2025	$7K	+133%	$65K
Q4 FY24	Dec 31, 2024	$11K	−15%	$61K
Q3 FY24	Sep 30, 2024	$34K	+36%	$63K
Q2 FY24	Jun 30, 2024	$13K	−52%	$54K
Q1 FY24	Mar 31, 2024	$3K	−95%	$68K
Q4 FY23	Dec 31, 2023	$13K	−100%	$130K
Q3 FY23	Sep 30, 2023	$25K	+733%	$48.5M

Companies in Drug Manufacturers - General nearest Lyell Immunopharma's size, closest first, today.

Company	Revenue, 12 months	Growth
LYELLyell Immunopharma	$27K	−55% a year
NATRNatures Sunshine Products	$492M	+7% a year
ARVNArvinas	$316.7M	−15% a year
PBYIPuma Biotechnology	$231.2M	−3% a year
IRWDIronwood Pharmaceuticals	$389.3M	+26% a year
ZVRAZevra Therapeutics	$136.1M	+119% a year
CRMDCorMedix	$462.2M	+281% a year
LFVNLifevantage	$182.6M	−20% a year
COLLCollegium Pharmaceutical	$808.2M	+14% a year
SPROSpero Therapeutics	$47M	−3% a year
ABUSArbutus Biopharma	$181.7M
Peer median	$274M